{"id":42200,"date":"2025-09-24T15:23:44","date_gmt":"2025-09-24T07:23:44","guid":{"rendered":"https:\/\/flcube.com\/?p=42200"},"modified":"2025-09-24T15:23:45","modified_gmt":"2025-09-24T07:23:45","slug":"jiangsu-hengrui-receives-nmpa-acceptance-for-shr7280-oral-gnrh-antagonist","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42200","title":{"rendered":"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>)<\/strong> announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has accepted the marketing application for its oral <strong>SHR7280<\/strong> tablet. The drug is designed to block premature luteinizing hormone (LH) surges in patients undergoing controlled ovarian stimulation (COS) as part of assisted reproductive technology (ART) protocols.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-overview\">Product Overview<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SHR7280<\/strong> is a small\u2011molecule <strong>GnRH receptor antagonist<\/strong> that competitively inhibits endogenous GnRH binding, thereby suppressing gonadotropin (LH and FSH) synthesis and release.<\/li>\n\n\n\n<li>The oral formulation offers a convenient alternative to the current injectable GnRH antagonists used in COS, potentially improving patient compliance and reducing clinic visits.<\/li>\n\n\n\n<li>No oral GnRH antagonists have yet received approval for assisted reproduction, either in China or abroad, placing SHR7280 as a first\u2011in\u2011class candidate.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-impact\">Clinical Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Benefit<\/th><th>Clinical Context<\/th><\/tr><\/thead><tbody><tr><td>Oral delivery<\/td><td><strong>Patient convenience<\/strong><\/td><td>Reduces the need for daily injections during COS cycles<\/td><\/tr><tr><td>Rapid LH suppression<\/td><td><strong>Prevents premature LH surges<\/strong><\/td><td>Enhances follicular recruitment and oocyte yield<\/td><\/tr><tr><td>Small\u2011molecule<\/td><td><strong>Potentially lower cost<\/strong><\/td><td>Makes the therapy accessible to a broader ART patient base<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The <strong>NMPA acceptance<\/strong> removes the final regulatory barrier before a commercial launch, allowing Jiangsu Hengrui to initiate post\u2011marketing studies and distribution plans.<\/li>\n\n\n\n<li>The decision aligns with China\u2019s strategic push to expand domestic fertility\u2011medicine innovation and reduce reliance on imported ART technologies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The global ART drug market is projected to exceed <strong>$3\u202fbillion<\/strong> by 2035; an oral GnRH antagonist could capture a significant share of this growing segment.<\/li>\n\n\n\n<li>Competitors such as <strong>Merck<\/strong> (Goserelin) and <strong>AbbVie<\/strong> (Cetrorelix) currently rely on injectable agents; SHR7280 may shift the therapeutic landscape toward oral solutions.<\/li>\n\n\n\n<li>Jiangsu Hengrui\u2019s move may accelerate the adoption of oral ART agents in Asia, potentially prompting similar approvals in other jurisdictions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600276_20250924_ZP46.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20250924_ZP46.\"><\/object><a id=\"wp-block-file--media-42d9335f-bca9-4545-91e3-046f9a70b834\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600276_20250924_ZP46.pdf\">600276_20250924_ZP46<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600276_20250924_ZP46.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-42d9335f-bca9-4545-91e3-046f9a70b834\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42202,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[234,2586,4228,38,120,852],"class_list":["post-42200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-abbvie","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-market-approval-filings","tag-merck","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA) has accepted the marketing application for its oral SHR7280 tablet. The drug is designed to block premature luteinizing hormone (LH) surges in patients undergoing controlled ovarian stimulation (COS) as part of assisted reproductive technology (ART) protocols.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42200\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42200\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-24T07:23:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-24T07:23:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2408.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42200#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42200\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist\",\"datePublished\":\"2025-09-24T07:23:44+00:00\",\"dateModified\":\"2025-09-24T07:23:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42200\"},\"wordCount\":302,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42200#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2408.webp\",\"keywords\":[\"AbbVie\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"Market approval filings\",\"Merck\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42200#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42200\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42200\",\"name\":\"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42200#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42200#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2408.webp\",\"datePublished\":\"2025-09-24T07:23:44+00:00\",\"dateModified\":\"2025-09-24T07:23:45+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA) has accepted the marketing application for its oral SHR7280 tablet. The drug is designed to block premature luteinizing hormone (LH) surges in patients undergoing controlled ovarian stimulation (COS) as part of assisted reproductive technology (ART) protocols.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42200#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42200\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42200#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2408.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2408.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42200#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA) has accepted the marketing application for its oral SHR7280 tablet. The drug is designed to block premature luteinizing hormone (LH) surges in patients undergoing controlled ovarian stimulation (COS) as part of assisted reproductive technology (ART) protocols.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42200","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=42200","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-24T07:23:44+00:00","article_modified_time":"2025-09-24T07:23:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2408.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42200#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42200"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist","datePublished":"2025-09-24T07:23:44+00:00","dateModified":"2025-09-24T07:23:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42200"},"wordCount":302,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42200#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2408.webp","keywords":["AbbVie","Hengrui Pharmaceuticals","HKG: 1276","Market approval filings","Merck","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42200#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42200","url":"https:\/\/flcube.com\/?p=42200","name":"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42200#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42200#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2408.webp","datePublished":"2025-09-24T07:23:44+00:00","dateModified":"2025-09-24T07:23:45+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA) has accepted the marketing application for its oral SHR7280 tablet. The drug is designed to block premature luteinizing hormone (LH) surges in patients undergoing controlled ovarian stimulation (COS) as part of assisted reproductive technology (ART) protocols.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42200#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42200"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42200#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2408.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2408.webp","width":1080,"height":608,"caption":"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42200#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2408.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42200"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42200\/revisions"}],"predecessor-version":[{"id":42203,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42200\/revisions\/42203"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42202"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}